Market Cap 383.78M
Revenue (ttm) 0.00
Net Income (ttm) -59.00M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 251,100
Avg Vol 342,572
Day's Range N/A - N/A
Shares Out 127.08M
Stochastic %K 79%
Beta 0.75
Analysts Strong Sell
Price Target $4.00

Company Profile

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis. It also provides nautilus voyager instrument, a high-resolution optical imaging system with integrated fluidics and liquid handling sub-system to...

Industry: Biotechnology
Sector: Healthcare
Phone: 206 333 2001
Address:
2701 Eastlake Avenue East, Seattle, United States
topstockalerts
topstockalerts May. 12 at 1:42 AM
$NAUT the trend keeps tightening up
0 · Reply
JackStrawFromWichitah
JackStrawFromWichitah May. 11 at 5:40 PM
$NAUT someone knows something
0 · Reply
ezMoney001
ezMoney001 May. 11 at 2:52 PM
$NAUT as per AI Conclusion. - there is no support or announcement that involved NAUT in this research ,, but it does make sense Nautilus Biotechnology's single-molecule proteomics platform could significantly contribute to Hantavirus vaccine development by providing unprecedented detail about viral protein structures, modifications, and interactions. However, it would likely serve as a complementary tool within a broader vaccine development pipeline rather than a standalone solution. The platform's ability to quantify proteoforms with high precision could be particularly valuable for identifying conserved targets for cross-protective vaccines and understanding the molecular basis of viral pathogenicity. Given the current lack of approved Hanta vaccines and the urgent need for effective treatments, advanced proteomics platforms like Nautilus's could accelerate the discovery and optimization of vaccine candidates by providing deeper molecular insights than currently available tech
0 · Reply
ezMoney001
ezMoney001 May. 11 at 1:55 PM
$NAUT https://www.youtube.com/watch?v=rDjDR_n6lGM
0 · Reply
ezMoney001
ezMoney001 May. 11 at 1:36 PM
$NAUT a day's worth of volume in 5 minutes? Don't see anything in pring? any ideas ....
0 · Reply
Rebooter
Rebooter May. 10 at 3:26 PM
$NAUT $QSI Inaccurate. Platinum/Proteus (Quantum-Si) is a protein sequencing platform, operating at single amino acid resolution. The closest direct competition is mass spectrometry. Voyager (Nautilus) is an affinity-based, single molecule platform for analysis of protein variations (proteoforms). The closest direct competition is a platform like SomaScan from Standard BioTools. If anything, the Voyager platform could be considered complementary to Platinum/Proteus, for downstream analysis of QSI output. Many core labs will utilize both. The market hasn't made a 'choice' in regards to either of them.
0 · Reply
HypnoTrader
HypnoTrader May. 9 at 4:37 PM
$NAUT and $QSI are direct competitors, although with different approaches to the same problem. Both are de facto pre-revenue. Yet naut is in uptrend, while qsi stuck in a range. Market made a choice?
2 · Reply
WOLFSTREET
WOLFSTREET May. 8 at 10:39 PM
$NAUT I have not been here 4 years, CC locked on to this Nov. 2025 in the 1s range. I do not follow analysts, do not know ultra-1 level stuff, am not a homie. CC operates on a whole other dimension. So I'm fine sharing and waiting to see what CC delivers.
0 · Reply
WOLFSTREET
WOLFSTREET May. 8 at 10:34 PM
$NAUT NICE! CC Needs this type of help for post gen
0 · Reply
WOLFSTREET
WOLFSTREET May. 8 at 10:33 PM
$NAUT Why do people set out in front of a high speed train instead of boarding it?
0 · Reply
Latest News on NAUT
Nautilus Biotechnology Earnings Call Transcript: Q1 2026

Apr 28, 2026, 8:30 AM EDT - 15 days ago

Nautilus Biotechnology Earnings Call Transcript: Q1 2026


Nautilus Biotechnology Earnings Call Transcript: Q4 2025

Feb 26, 2026, 8:30 AM EST - 2 months ago

Nautilus Biotechnology Earnings Call Transcript: Q4 2025


Nautilus Biotechnology reports Q4 EPS (11c) vs (14c) last year

2026-02-26T13:21:03.000Z - 2 months ago

Nautilus Biotechnology reports Q4 EPS (11c) vs (14c) last year


Nautilus Biotechnology unveils Voyager Platform

2026-02-24T13:16:26.000Z - 2 months ago

Nautilus Biotechnology unveils Voyager Platform


Nautilus Biotechnology Earnings Call Transcript: Q3 2025

Oct 28, 2025, 8:30 AM EDT - 7 months ago

Nautilus Biotechnology Earnings Call Transcript: Q3 2025


Nautilus Biotechnology reports Q3 EPS (11c) vs (13c) last year

2025-10-28T12:05:14.000Z - 7 months ago

Nautilus Biotechnology reports Q3 EPS (11c) vs (13c) last year


Nautilus Biotechnology jumps after Amazon discloses $1M stake

2025-08-05T20:47:24.000Z - 10 months ago

Nautilus Biotechnology jumps after Amazon discloses $1M stake


Nautilus Biotechnology Earnings Call Transcript: Q2 2025

Jul 31, 2025, 8:30 AM EDT - 10 months ago

Nautilus Biotechnology Earnings Call Transcript: Q2 2025


Nautilus Biotechnology reports Q2 EPS (12c) vs (14c) last year

2025-07-31T12:05:40.000Z - 10 months ago

Nautilus Biotechnology reports Q2 EPS (12c) vs (14c) last year


Nautilus Biotechnology enters agreement with Allen Institute

2025-07-30T12:27:07.000Z - 10 months ago

Nautilus Biotechnology enters agreement with Allen Institute


Nautilus Biotechnology Earnings Call Transcript: Q1 2025

Apr 29, 2025, 8:30 AM EDT - 1 year ago

Nautilus Biotechnology Earnings Call Transcript: Q1 2025


Nautilus Biotechnology reports Q1 EPS (13c), consensus (14c)

2025-04-29T12:05:38.000Z - 1 year ago

Nautilus Biotechnology reports Q1 EPS (13c), consensus (14c)


Nautilus Biotechnology Earnings Call Transcript: Q4 2024

Feb 27, 2025, 8:30 AM EST - 1 year ago

Nautilus Biotechnology Earnings Call Transcript: Q4 2024


Nautilus Biotechnology reports Q4 EPS (14c), consensus (18c)

2025-02-27T13:18:38.000Z - 1 year ago

Nautilus Biotechnology reports Q4 EPS (14c), consensus (18c)


Nautilus Biotechnology Earnings Call Transcript: Q3 2024

Oct 29, 2024, 8:30 AM EDT - 1 year ago

Nautilus Biotechnology Earnings Call Transcript: Q3 2024


Nautilus Biotechnology reports Q3 EPS (13c), consensus (16c)

2024-10-29T12:05:50.000Z - 1 year ago

Nautilus Biotechnology reports Q3 EPS (13c), consensus (16c)


Nautilus Biotechnology Earnings Call Transcript: Q2 2024

Jul 30, 2024, 8:30 AM EDT - 1 year ago

Nautilus Biotechnology Earnings Call Transcript: Q2 2024


Nautilus Biotechnology reports Q2 EPS (14c), consensus (16c)

2024-07-30T12:06:24.000Z - 1 year ago

Nautilus Biotechnology reports Q2 EPS (14c), consensus (16c)


Nautilus Biotechnology Earnings Call Transcript: Q1 2024

Apr 30, 2024, 8:30 AM EDT - 2 years ago

Nautilus Biotechnology Earnings Call Transcript: Q1 2024


Nautilus Biotechnology Earnings Call Transcript: Q4 2023

Feb 28, 2024, 8:30 AM EST - 2 years ago

Nautilus Biotechnology Earnings Call Transcript: Q4 2023


Nautilus Biotechnology Earnings Call Transcript: Q3 2023

Oct 31, 2023, 8:30 AM EDT - 2 years ago

Nautilus Biotechnology Earnings Call Transcript: Q3 2023


Nautilus Biotechnology Earnings Call Transcript: Q2 2023

Aug 2, 2023, 8:30 AM EDT - 3 years ago

Nautilus Biotechnology Earnings Call Transcript: Q2 2023


Nautilus Biotechnology Earnings Call Transcript: Q1 2023

May 2, 2023, 8:30 AM EDT - 3 years ago

Nautilus Biotechnology Earnings Call Transcript: Q1 2023


Nautilus Biotechnology Earnings Call Transcript: Q4 2022

Feb 23, 2023, 8:30 AM EST - 3 years ago

Nautilus Biotechnology Earnings Call Transcript: Q4 2022


Nautilus Biotechnology Expands to San Diego

Jan 26, 2023, 7:45 AM EST - 3 years ago

Nautilus Biotechnology Expands to San Diego


Nautilus Biotechnology Earnings Call Transcript: Q3 2022

Nov 1, 2022, 8:30 AM EDT - 3 years ago

Nautilus Biotechnology Earnings Call Transcript: Q3 2022


Nautilus Biotechnology Earnings Call Transcript: Q2 2022

Aug 1, 2022, 10:58 PM EDT - 4 years ago

Nautilus Biotechnology Earnings Call Transcript: Q2 2022


Nautilus Biotechnology to Present at EuPA and AACR Meetings

Apr 4, 2022, 8:00 AM EDT - 4 years ago

Nautilus Biotechnology to Present at EuPA and AACR Meetings


topstockalerts
topstockalerts May. 12 at 1:42 AM
$NAUT the trend keeps tightening up
0 · Reply
JackStrawFromWichitah
JackStrawFromWichitah May. 11 at 5:40 PM
$NAUT someone knows something
0 · Reply
ezMoney001
ezMoney001 May. 11 at 2:52 PM
$NAUT as per AI Conclusion. - there is no support or announcement that involved NAUT in this research ,, but it does make sense Nautilus Biotechnology's single-molecule proteomics platform could significantly contribute to Hantavirus vaccine development by providing unprecedented detail about viral protein structures, modifications, and interactions. However, it would likely serve as a complementary tool within a broader vaccine development pipeline rather than a standalone solution. The platform's ability to quantify proteoforms with high precision could be particularly valuable for identifying conserved targets for cross-protective vaccines and understanding the molecular basis of viral pathogenicity. Given the current lack of approved Hanta vaccines and the urgent need for effective treatments, advanced proteomics platforms like Nautilus's could accelerate the discovery and optimization of vaccine candidates by providing deeper molecular insights than currently available tech
0 · Reply
ezMoney001
ezMoney001 May. 11 at 1:55 PM
$NAUT https://www.youtube.com/watch?v=rDjDR_n6lGM
0 · Reply
ezMoney001
ezMoney001 May. 11 at 1:36 PM
$NAUT a day's worth of volume in 5 minutes? Don't see anything in pring? any ideas ....
0 · Reply
Rebooter
Rebooter May. 10 at 3:26 PM
$NAUT $QSI Inaccurate. Platinum/Proteus (Quantum-Si) is a protein sequencing platform, operating at single amino acid resolution. The closest direct competition is mass spectrometry. Voyager (Nautilus) is an affinity-based, single molecule platform for analysis of protein variations (proteoforms). The closest direct competition is a platform like SomaScan from Standard BioTools. If anything, the Voyager platform could be considered complementary to Platinum/Proteus, for downstream analysis of QSI output. Many core labs will utilize both. The market hasn't made a 'choice' in regards to either of them.
0 · Reply
HypnoTrader
HypnoTrader May. 9 at 4:37 PM
$NAUT and $QSI are direct competitors, although with different approaches to the same problem. Both are de facto pre-revenue. Yet naut is in uptrend, while qsi stuck in a range. Market made a choice?
2 · Reply
WOLFSTREET
WOLFSTREET May. 8 at 10:39 PM
$NAUT I have not been here 4 years, CC locked on to this Nov. 2025 in the 1s range. I do not follow analysts, do not know ultra-1 level stuff, am not a homie. CC operates on a whole other dimension. So I'm fine sharing and waiting to see what CC delivers.
0 · Reply
WOLFSTREET
WOLFSTREET May. 8 at 10:34 PM
$NAUT NICE! CC Needs this type of help for post gen
0 · Reply
WOLFSTREET
WOLFSTREET May. 8 at 10:33 PM
$NAUT Why do people set out in front of a high speed train instead of boarding it?
0 · Reply
WOLFSTREET
WOLFSTREET May. 8 at 10:32 PM
$NAUT Mikey Likey!
0 · Reply
WOLFSTREET
WOLFSTREET May. 8 at 10:19 PM
$NAUT Idiots digging this up w/o any context, down 22 % but up 55 % from getting started with posting about it. Idiots will eventually cry. When it comes to CC, there is no substitute, particular on current version 9.7
0 · Reply
Johnny_Lever
Johnny_Lever May. 8 at 10:14 PM
$NAUT @WOLFSTREET Absolutely not, this is about bullshit CC9.XXXX.
0 · Reply
WOLFSTREET
WOLFSTREET May. 8 at 10:12 PM
$NAUT @Johnny_Lever rewind a bit more, I'm glad I am renting space in your head, up over 50% and super early. Not random, precise. Not silly lines. And NOT leaving.
0 · Reply
WOLFSTREET
WOLFSTREET May. 8 at 10:10 PM
$NAUT Absolutely not, this is not about lines, this is about knowing.
0 · Reply
Johnny_Lever
Johnny_Lever May. 8 at 10:07 PM
$NAUT @WOLFSTREET Hope you left. It went bigly ugly after your rant about not leaving. 😂
0 · Reply
CuentaGanadora
CuentaGanadora May. 8 at 8:33 PM
$NAUT 10% up after hours. 🥲
0 · Reply
Nosecandy_Bear
Nosecandy_Bear May. 8 at 4:33 PM
$ALAB $BETA $MRVL $NAUT $RIVN Amazon is down billions on Rivian.
0 · Reply
tievLeaf
tievLeaf May. 8 at 3:01 PM
$QSI Finally to all of you folks, don't be fooled by the drop. Just DCA. READ THE EARNING TRANSCRIPTS CAREFULLY. THIS IS INCREDIBLY BULLISH and I will not expect this dip to last. Everything I pasted here including this one final line I will paste just makes me want to seriously add much more than I can possibly could right now. "We are working closely with our manufacturing partners to increase the number of Proteus instruments available within our R&D labs" They are INCREASING proteus instruments manufacturing folks. There is HIGH level of customer interests and the fact that they are doubling down on Proteus shows how strong the demand can be here. DO NOT be fooled by short sellers or the drop. I remain confident that this will not last and a bounce is quite likely. https://finance.yahoo.com/quote/QSI/earnings/QSI-Q1-2026-earnings_call-579855.html $QQQ $SPY $NAUT $SLS
2 · Reply
tievLeaf
tievLeaf May. 7 at 2:59 PM
$NAUT Everyone talks about Nautilus Biotechnology like it already owns some massive AI-ready proteomics dataset, but where is it? They’ve placed just ONE early access system at Baylor College of Medicine and are still guiding broader commercial rollout around 2027 compared to $QSI. That means customer adoption and real-world dataset generation are still years away. AI labs like Anthropic do not pay up for potential connections or shared academic circles. They pay for proprietary data at scale, generated consistently across thousands of samples and conditions which NAUT does not have compared to $QSI which they have already mentioned in their Q3 transcript that they have the richest proprietary set of proteomic data in the industry. Right now NAUT has an interesting platform and a compelling vision, but no broad installed base, no deep commercial dataset and ZERO PROOF it can become the protein data backbone bulls keep hyping. Story sounds big. Actual output is still tiny the end.
0 · Reply
Rebooter
Rebooter May. 7 at 1:25 PM
$NAUT Just one flaw with your 'thesis' homeboy, NAUT doesn't have any data. They've placed a grand total of one early access unit, and I guarantee you that thing is being held together with bailing wire and bubblegum. That plus a handful of internal runs won't yield a dataset that's deep or wide enough to be of interest to Anthropic or anyone else.
1 · Reply
tievLeaf
tievLeaf May. 7 at 8:52 AM
$NAUT 165 volume on this is insane, this will likely go down to 1s over time
0 · Reply